Oncology Peer Review On-The-Go: A Critical Interval to Delay Progression of Prostate Cancer
E. David Crawford, MD, spoke about the use of transitional disease and other redefined disease states in prostate cancer, while Rana McKay, MD emphasized the need for clinical trials to validate current treatments and practices.
This episode features an article published in the April issue of the Journal ONCOLOGY® titled “Focus on Transitional Disease: A Critical Interval to Delay Progression of Prostate Cancer.” The lead author of the research, E. David Crawford, MD, a urologic oncologist and professor of urology at the University of California San Diego, explained his research into prostate cancer disease states. Among other things, Crawford and the research team talked about next-generation imaging, biomarkers, and redefined prostate cancer disease states to introduce transitional disease into that equation.
The response perspective for this article comes from Rana McKay, MD, an associate professor of medicine and urology at the University of California San Diego. McKay provided some of her thoughts on the idea of redefining prostate cancer disease states and really emphasized the need for clinical research to validate treatment options and current practices.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.
Data Support Early Genetic Testing in HRR+ mCRPC Managed With Olaparib
January 27th 2024Testing for HRR status prior to a diagnosis of metastatic castration-resistant prostate cancer may allow for earlier treatment and potentially greater clinical benefit with olaparib, according to Daniel J. George, MD.
